A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.
Clinical Trials
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Combined BRAF-MEK inhibition for advanced BRAF-mutant melanoma led to significantly better progression-free survival (PFS) as compared with single-agent BRAF inhibition, according to a randomized trial.
Biomarker Analysis Contextualizes RFS Benefit With Nivolumab in Metastatic Melanoma
Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
Worse Outcomes Found Among Melanoma Patients Whose Brain Metastases Have BRAF V600E Alterations
Patients with melanoma brain metastases that have BRAF V600E alterations have worse outcomes, according to a new analysis appearing in JAMA Network Open.